Inhibition of tumor angiogenesis by oral etoposide

Experimental and Therapeutic Medicine

Volumn 1, Issue 5, 2010, Pages 739-746

  Panigrahy, Dipak ^a,b   Kaipainen, Arja ^c   Butterfield, Catherine E ^a   Chaponis, Deviney M ^a,b   Laforme, Andrea M ^a,b   Folkman, Judah ^a   Kieran, Mark W ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Etoposide; Metronomic chemotherapy; Oral combination therapy; Peroxisome proliferator activated receptor; Tumor angiogenesis

Indexed keywords

CELECOXIB; CYCLOPHOSPHAMIDE; ENDOSTATIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR 2; ROSIGLITAZONE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; FIBROSARCOMA; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LOW DRUG DOSE; LUNG METASTASIS; METASTASIS; MONOTHERAPY; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIMARY TUMOR; PROTEIN SYNTHESIS INHIBITION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 77955177425     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2010.127     Document Type: Article

References (50)

1. Browder T, Butterfield CE, Kraling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2000.
2. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. JClin Invest 105: 15-24, 2000.
3. Hanahan D, Bergers G and Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. JClin Invest 105: 1045-1047, 2000.
4. Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436, 2004.
5. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286, 2007.
6. Man S, Bocci G, Francia G, et al: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62: 2731-2735, 2002.
7. Kieran MW, Turner CD, Rubin J, et al: Afeasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. JPediatr Hematol Oncol 27: 573-581, 2005.
8. Vogt T, Hafner C, Bross K, et al: Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98: 2251-2256, 2003.
9. Sterba J, Valik D, Mudry P, et al: Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie 29: 308-313, 2006.
10. Aisner J and Lee EJ: Etoposide. Current and future status. Cancer 67: 215-219, 1991.
11. Kakolyris S, Samonis G, Koukourakis M, et al: Treatment of non-small cell lung cancer with prolonged oral etoposide. Am JClin Oncol 21: 505-508, 1998.
12. Ashley DM, Meier L, Kerby T, et al: Response of recurrent medulloblastoma to low-dose oral etoposide. JClin Oncol 14: 1922-1927, 1996.
13. Alici S, Saip P, Eralp Y, Aydiner A and Topuz E: Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). Am JClin Oncol 26: 358-362, 2003.
14. Martin M, Lluch A, Casado A, et al: Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. JClin Oncol 12: 986-991, 1994.
15. Kebudi R, Gorgun O and Ayan I: Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatr Blood Cancer 42: 320-324, 2004.
16. Cavalli F, Sonntag RW, Jungi F, Senn HJ and Brunner KW: VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 62: 473-475, 1978.
17. Bontenbal M, Planting AS, Verweij J, et al: Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer. Breast Cancer Res Treat 34: 185-189, 1995.
18. Folkman J: Tumor angiogenesis. In: Cancer Medicine. HollandJF, Frei EI, Bast RCJ, Kufe DW, Pollock RE and Weichselbaum RR(eds). 5th edition. BCDecker Inc., Ontario, pp132-152, 2000.
19. Ma G, Masuzawa M, Hamada Y, et al: Treatment of murine angiosarcoma with etoposide, TNP-470 and prednisolone. JDermatol Sci 24: 126-133, 2000.
20. Drevs J, Fakler J, Eisele S, et al: Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 24: 1759-1763, 2004.
21. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
22. Panigrahy D, Singer S, Shen LQ, et al: PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. JClin Invest 110: 923-932, 2002.
23. Kamiyama H, Takano S, Tsuboi K and Matsumura A: Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. JCancer Res Clin Oncol 131: 205-213, 2005.
24. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. JClin Oncol 20: 4368-4380, 2002.
25. Hong SY, Lee MH, Kim KS, et al: Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model. World JGastroenterol 10: 1191-1197, 2004.
26. Sant VP, Nagarsenker MS, Rao SG and Gude RP: Sterically stabilized etoposide liposomes: evaluation of antimetastatic activity and its potentiation by combination with sterically stabilized pentoxifylline liposomes in mice. Cancer Biother Radiopharm 18: 811-817, 2003.
27. Masferrer JL, Leahy KM, Koki A, et al: Antiangiogenic and antitumor activities of cyclooxgenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
28. Kerbel RS: Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312: 1171-1175, 2006.
29. Shaked Y, Emmenegger U, Francia G, et al: Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 65: 7045-7051, 2005.
30. Bocci G, Nicolaou KC and Kerbel RS: Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62: 6938-6943, 2002.
31. Hamano Y, Sugimoto H, Soubasakos MA, et al: Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64: 1570-1574, 2004.
32. Needle MN, Molloy PT, Geyer JR, et al: Phase IIstudy of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 29: 28-32, 1997.
33. Doll DC, Kasper LM, Taetle R and List AF: Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes. Leuk Res 22: 7-12, 1998.
34. Hainsworth JD: Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues. Drugs 58 (Suppl 3): 51-56, 1999.
35. Zucchetti M, Pagani O, Torri V, et al: Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer. Clin Cancer Res 1: 1517-1524, 1995.
36. Lowis SP, Newell DR and Pearson AD: Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro. Eur JCancer 31A: 622-626, 1995.
37. Dombernowsky P and Nissen NI: Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microbiol Scand [A] 81: 715-724, 1973.
38. Schirner M, Hoffmann J, Menrad A and Schneider MR: Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 4: 1331-1336, 1998.
39. Nilsson UW and Dabrosin C: Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo. Cancer Res 66: 4789-4794, 2006.
40. Ma L, del Soldato P and Wallace JL: Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad Sci USA99: 13243-13247, 2002.
41. Nagashima M, Asano G and Yoshino S: Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. JRheumatol 27: 2339-2342, 2000.
42. Yu JL, Rak JW, Coomber BL, Hicklin DJ and Kerbel RS: Effect of p53 status on tumor response to antiangiogenic therapy. Science 295: 1526-1528, 2002.
43. Yap R, Veliceasa D, Emmenegger U, et al: Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. ClinClin Cancer Res 11: 6678-6685, 2005.
44. Girnun GD, Naseri E, Vafai SB, et al: Synergy between PPAR gamma ligands and platinum-based drugs in cancer. Cancer Cell 11: 395-406, 2007.
45. Khafif A, Canfield VA, Syzek EJ and Medina JE: Results of phase I-IItrial of concomitant hyperfractionated radiation and oral etoposide (VP-16) in patients with unresectable squamous cell carcinoma of the head and neck. Am JOtolaryngol 24: 1-5, 2003.
46. Vaishampayan U, Fontana J, Du W and Hussain M: Phase IItrial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma. Am JClin Oncol 27: 550-554, 2004.
47. Bocci G, Tuccori M, Emmenegger U, et al: Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. Acomparative pharmacoeconomic evaluation. Ann Oncol 16: 1243-1252, 2005.
48. Vanchieri C: When will the U.S. flinch at cancer drug prices? J Natl Cancer Inst 97: 624-626, 2005.
49. Emmenegger U, Morton GC, Francia G, et al: Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 66: 1664-1674, 2006.
50. Verdrengh M and Tarkowski A: Impact of topoisomerase IIinhibition on cytokine and chemokine production. Inflamm Res 52: 148-153, 2003.